$BLSM News
Last published 15h ago
- 15h agoBLSMBlossomHill Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 15h agoBLSMBlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireAlignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to date
- 4d agoBLSMBlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLCGlobeNewswireAlignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate
- 1w agoBLSMBlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual MeetingGlobeNewswireSAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative
- 1w agoBLSMBlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations ConferenceGlobeNewswireSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative
- 3w agoBLSMBlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung CancerGlobeNewswireSAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative
- 1mo agoBLSMBlossomHill Therapeutics Reports Second Quarter 2026 Financial ResultsGlobeNewswireStrengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN
- 1mo agoBLSMBlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung CancerGlobeNewswire45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no
- 2mo agoBLSMBlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative
- 2mo agoBLSMBlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung CancerGlobeNewswireData to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by
- 2mo agoBLSMBlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLCGlobeNewswireSAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative
- 3mo agoBLSMBlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public OfferingGlobeNewswireSAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., ("BlossomHill Therapeutics"), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to